Early Human Development
Volume 86, Issue 6 , Pages 369-377 , June 2010

Experimental treatments for hypoxic ischaemic encephalopathy

References 

  1. Lawn JECS, Zupan J. Lancet Neonatal Survival Steering Team. 4 million neonatal deaths: When? Where? Why?. Lancet. 2005;365:891–900
  2. Pierrat VHN, Liska A, Thomas D, Subtil D, Truffert P. Groupe d'Etudes en Epidemiologie Perinatale. Prevalence, causes, and outcome at 2years of age of newborn encephalopathy: population based study. Arch Dis Child Fetal Neonatal Ed. 2005;90:F257–261
  3. Marlow N, Budge H. Prevalence, causes, and outcome at 2years of age of newborn encephalopathy. Arch Dis Child Fetal Neonatal Ed. 2005;90:193–194
  4. Cowan F. Outcome after intrapartum asphyxia in term infants. Semin Neonatol. 2000;5:127–140
  5. Al-Macki N, Miller SP, Hall N, Shevell M. The spectrum of abnormal neurologic outcomes subsequent to term intrapartum asphyxia. Pediatr Neurol. 2009;41:399–405
  6. Bona E, Hagberg H, Løberg E, Bågenholm R, Thoresen M. Protective effects of moderate hypothermia after neonatal hypoxia-ischemia: short- and long-term outcome. Pediatr Res. 1998;43:738–745
  7. Gluckman PD, Wyatt JS, Azzopardi D, Ballard R, Edwards AD, Ferriero DM, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet. 2005;365:663–670
  8. Edwards A, Brocklehurst P, Gunn A, Halliday H, Juszczak E, Levene M, et al. Neurological outcomes at 18months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data. BMJ. 2010;340:C363;doi: 310.1136/bmj.c1363
  9. Kapetanakis A, Azzopardi D, Wyatt J, Robertson N. Therapeutic hypothermia for neonatal encephalopathy: a UK survey of opinion, practice and neuro-investigation at the end of 2007. Acta Paediatr. 2009;98:631–635
  10. O'Brien F, Iwata O, Thornton J, De Vita E, Sellwood M, Iwata S, et al. Delayed whole-body cooling to 33 or 35 degrees c and the development of impaired energy generation consequential to transient cerebral hypoxia-ischemia in the newborn piglet. Pediatrics. 2006;117:1549–1559
  11. Liu Y, Barks J, Xu G, Silverstein F. Topiramate extends the therapeutic window for hypothermia-mediated neuroprotection after stroke in neonatal rats. Stroke. 2004;35:1460–1465
  12. Ma D, Hossain M, Chow A, Arshad M, Battson R, Sanders R, et al. Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia. Ann Neurol. 2005;58:182–193
  13. Jatana M, Singh I, Singh A, Jenkins D. Combination of systemic hypothermia and n-acetylcysteine attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr Res. 2006;59:684–689
  14. Ramaswamy V, Horton J, Vandermeer B, Buscemi N, Miller S, Yager J. Systematic review of biomarkers of brain injury in term neonatal encephalopathy. Pediatr Neurol. 2009;40:215–226
  15. Edwards A. The discovery of hypothermic neural rescue therapy for perinatal hypoxic-ischemic encephalopathy. Semin Pediatr Neurol. 2009;16:200–206
  16. Thoresen M, Penrice J, Lorek A, Cady E, Wylezinska M, Kirkbride V, et al. Mild hypothermia after severe transient hypoxia-ischemia ameliorates delayed cerebral energy failure in the newborn piglet. Pediatr Res. 1995;37:667–670
  17. Rutherford M, Ramenghi L, Edwards A, Brocklehurst P, Halliday H, Levene M, et al. Assessment of brain tissue injury after moderate hypothermia in neonates with hypoxic-ischaemic encephalopathy: a nested substudy of a randomised controlled trial. Lancet Neurol. 2010;9:39–45
  18. Robertson N, Cox I, Cowan F, Counsell S, Azzopardi D, Edwards A. Cerebral intracellular lactic alkalosis persisting months after neonatal encephalopathy measured by magnetic resonance spectroscopy. Pediatr Res. 1999;46:287–296
  19. Thayyil S, Chandrasekaran M, Taylor A, Bainbridge A, Cady E, Chong K, et al. Cerebral magnetic resonance biomarkers in neonatal encephalopathy: a meta-analysis. Pediatrics. 2010;125:e382–395
  20. Parsons MW, Li T, Barber PA, Yang Q, Darby DG, Desmond PM, et al. Combined (1)h mr spectroscopy and diffusion-weighted mri improves the prediction of stroke outcome. Neurology. 2000;55:498–505
  21. Chandrasekaran M, Faulkner S, Bainbridge A, Kato T, Cady E, Kapetanakis A, et al. Xenon combined with hypothermia reduces cerebral Lactate/Cr on 1H MRS, markers of cell death and phagocytosis at 48hours in a perinatal asphyxia piglet model. EPAS. 2010;26327
  22. Azzopardi D, Wyatt J, Cady E, Delpy D, Baudin J, Stewart A, et al. Prognosis of newborn infants with hypoxic-ischemic brain injury assessed by phosphorus magnetic resonance spectroscopy. Pediatr Res. 1989;25:445–451
  23. Lei H, Peeling J. Effect of temperature on the kinetics of lactate production and clearance in a rat model of forebrain ischemia. Biochem Cell Biol. 1998;76:503–509
  24. Penrice J, Lorek A, Cady EB, Amess PN, Wylezinska M, Cooper CE, et al. Proton magnetic resonance spectroscopy of the brain during acute hypoxia-ischemia and delayed cerebral energy failure in the newborn piglet. Pediatr Res. 1997;41:795–802
  25. Lei H, Berthet C, Hirt L, Gruetter R. Evolution of the neurochemical profile after transient focal cerebral ischemia in the mouse brain. J Cereb Blood Flow Metab. 2009;29:811–819
  26. Rothman DL, Howseman AM, Graham GD, Petroff OA, Lantos G, Fayad PB, et al. Localized proton nmr observation of [3-13c]lactate in stroke after [1-13c]glucose infusion. Magn Reson Med. 1991;21:302–307
  27. Hanrahan JD, Cox IJ, Edwards AD, Cowan FM, Sargentoni J, Bell JD, et al. Persistent increases in cerebral lactate concentration after birth asphyxia. Pediatr Res. 1998;44:304–311
  28. Robertson N, Cowan F, Cox I, Edwards A. Brain alkaline intracellular ph after neonatal encephalopathy. Ann Neurol. 2002;52:732–742
  29. Mehmet H, Yue X, Penrice J, Cady E, Wyatt J, Sarraf C, et al. Relation of impaired energy metabolism to apoptosis and necrosis following transient cerebral hypoxia-ischaemia. Cell Death Differ. 1998;5:321–329
  30. Garcia JH. Cerebral infarction. Evolution of histopathological changes after occlusion of a middle cerebral artery in primates. J nNeuropathol Exp Neurol. 1974;33:408–421Y K
  31. Ramsay W. An attempt to estimate the relative amounts of krypton and of xenon in atmospheric ai. Proc R Soc Lond. 1902;71:421–426doi :410.1098/rspl.1902.0121
  32. Cullen S, Gross E. The anesthetic properties of xenon in animals and human beings, with additional observations on krypton. Science. 1951;113:580–582
  33. Franks N, Dickinson R, de Sousa S, Hall A, Lieb W. How does xenon produce anaesthesia?. Nature. 1998;26:324
  34. Lane GA, Nahrwold ML, Tait AR, Taylor-Busch M, Cohen PJ, Beaudoin AR. Anesthetics as teratogens: nitrous oxide is fetotoxic, xenon is not. Science. 1980;210:899–901
  35. Ma D, Williamson P, Januszewski A, Nogaro MC, Hossain M, Ong LP, et al. Xenon mitigates isoflurane-induced neuronal apoptosis in the developing rodent brain. Anaesthesiology. 2007;106:746–753
  36. Istaphanous G, Loepke A. General anesthetics and the developing brain. Curr Opin Anaesthesiol. 2009;22:368–373
  37. Coburn M, Kunitz O, Baumert JH, Hecker K, Haaf S, Zühlsdorff A, et al. Randomized controlled trial of the haemodynamic and recovery effects of xenon or propofol anaesthesia. Br J Anaesth. 2005;94:198–202
  38. Preckel B, Schlack W, Heibel T, Rütten R. Xenon produces minimal haemodynamic effects in rabbits with chronically compromised left ventricular function. Br J Anaesth. 2002;2002:2
  39. Greisen G. Intravenous 133xe clearance in preterm neonates with respiratory distress. Internal validation of cbf infinity as a measure of global cerebral blood flow. Scand J Clin Lab Invest. 1988;48:673–678O P
  40. Goto T, Saito H, Shinkai M, Nakata Y, Ichinose F, Morita S. Xenon provides faster emergence from anesthesia than does nitrous oxide-sevoflurane or nitrous oxide-isoflurane. Anaesthesiology. 1997;1997:6
  41. Gruss M, Bushell TJ, Bright DP, Lieb WR, Mathie A, Franks NP. Two-pore-domain k+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Mol Pharmacol. 2004;65:443–452
  42. Petzelt CP, Kodirov S, Taschenberger G, Kox WJ. Participation of the ca(2+)-calmodulin-activated kinase ii in the control of metaphase-anaphase transition in human cells. Cell Biol Int. 2001;25:403–409
  43. Ma DLT, Xu J, Tang H, Wan Y, Zhao H, Hossain M, et al. Xenon preconditioning protects against renal ischemic-reperfusion injury via hif-1alpha activation. J Am Soc Nephrol. 2009;20:713–720
  44. Dingley JTJ, Porter H, Thoresen M. Xenon provides short-term neuroprotection in neonatal rats when administered after hypoxia-ischemia. Stroke. 2006;37:501–506
  45. Martin JLMD, Hossain M, Xu J, Sanders RD, Franks NP, Maze M. Asynchronous administration of xenon and hypothermia significantly reduces brain infarction in the neonatal rat. Br J Anaesth. 2007;98:236–240
  46. Thoresen MHC, Wood T, Chakkarapani E, Dingley J. Cooling combined with immediate or delayed xenon inhalation provides equivalent long-term neuroprotection after neonatal hypoxia-ischemia. J Cereb Blood Flow Metab. 2009;29:707–714
  47. Jawad N, Rizvi M, Gu J, Adeyi O, Tao G, Maze M, et al. Neuroprotection (and lack of neuroprotection) afforded by a series of noble gases in an in vitro model of neuronal injury. Neurosci Lett. 2009;460:232–236
  48. Palmer C, Towfighi J, Roberts RL, Heitjan DF. Allopurinol administered after inducing hypoxia-ischemia reduces brain injury in 7-day-old rats. Pediatr Res. 1993;33:405–411
  49. Williams GD, Palmer C, Heitjan DF, Smith MB. Allopurinol preserves cerebral energy metabolism during perinatal hypoxia-ischemia: a 31p nmr study in unanesthetized immature rats. Neurosci Lett. 1992;144:103–106
  50. Johnson WD, Kayser KL, Brenowitz JB, Saedi SF. A randomized controlled trial of allopurinol in coronary bypass surgery. Am Heart J. 1991;121:20–24
  51. Clancy RR, McGaurn SA, Goin JE, Hirtz DG, Norwood WI, Gaynor JW, et al. Allopurinol neurocardiac protection trial in infants undergoing heart surgery using deep hypothermic circulatory arrest. Pediatrics. 2001;108:61–70
  52. van Kesteren C, Benders MJ, Groenendaal F, van Bel F, Ververs FF, Rademaker CM. Population pharmacokinetics of allopurinol in full-term neonates with perinatal asphyxia. Ther Drug Monit. 2006;28:339–344
  53. Chaudhari TWM. Allopurinol for preventing mortality and morbidity in newborn infants with suspected hypoxic-ischaemic encephalopathy. Cochrane Database Sys Rev. 2008;2:CD006817
  54. Benders MJ, Bos AF, Rademaker CM, Rijken M, Torrance HL, Groenendaal F, et al. Early postnatal allopurinol does not improve short term outcome after severe birth asphyxia. Arch Dis Child. 2006;91:F163–165
  55. Gunes T, Ozturk MA, Koklu E, Kose K, Gunes I. Effect of allopurinol supplementation on nitric oxide levels in asphyxiated newborns. Pediatr Neurol. 2007;36:17–24
  56. Van Bel F, Shadid M, Moison RM, Dorrepaal CA, Fontijn J, Monteiro L, et al. Effect of allopurinol on postasphyxial free radical formation, cerebral hemodynamics, and electrical brain activity. Pediatrics. 1998;101:185–193
  57. Torrance HL, Benders MJ, Derks JB, Rademaker CM, Bos AF, Van Den Berg P, et al. Maternal allopurinol during fetal hypoxia lowers cord blood levels of the brain injury marker s-100b. Pediatrics. 2009;124:350–357
  58. Kaandorp JJ, Benders MJ, Rademaker CM, Torrance HL, Oudijk MA, de Haan TR, et al. Antenatal allopurinol for reduction of birth asphyxia induced brain damage (allo-trial); a randomized double blind placebo controlled multicenter study. BMC Pregnancy Childbirth. 2010;10
  59. Kortsalioudaki C, Taylor R, Cheeseman P, Bansal S, Mieli-Vergani G, Dhawan A. Safety and efficacy of n-acetylcysteine in children with non-acetaminophen-induced acute liver failure. Liver Transpl. 2008;14:25–30
  60. Misra D, Leibowitz K, Gowda R, Shapiro M, Khan I. Role of n-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis. Clin Cardiol. 2004;27:607–610
  61. Khan M, Sekhon B, Jatana M, Giri S, Gilg A, Sekhon C, et al. Administration of n-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke. J Neurosci Res. 2004;76:519–527
  62. Wang X, Svedin P, Nie C, Lapatto R, Zhu C, Gustavsson M, et al. N-acetylcysteine reduces lipopolysaccharide-sensitized hypoxic-ischemic brain injury. Ann Neurol. 2007;61:263–271
  63. Paintlia MK, Paintlia AS, Barbosa E, Singh I. N-acetylcysteine prevents endotoxin-induced degeneration of oligodendrocyte progenitors and hypomyelination in developing rat brain. J Neurosci Res. 2004;78:347–361AK. S
  64. Paintlia MK, Paintlia AS, Singh AK, Singh I. Attenuation of lipopolysaccharide-induced inflammatory response and phospholipids metabolism at the feto-maternal interface by n-acetyl cysteine. Pediatr Res. 2008;64:334–339
  65. Lee T, Tymafichuk C, Bigam D, Cheung PY. Effects of postresuscitation n-acetylcysteine on cerebral free radical production and perfusion during reoxygenation of hypoxic newborn piglets. Pediatr Res. 2008;64:256–261
  66. Cakir O, Erdem K, Oruc A, Kilinc N, Eren N. Neuroprotective effect of n-acetylcysteine and hypothermia on the spinal cord ischemia-reperfusion injury. Cardiovasc Surg. 2003;11:375–379
  67. Pei Z, Pang SF, Cheung RT. Pretreatment with melatonin reduces volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. J Pineal Res. 2002;32:168–172
  68. Pei Z, Pang S, Cheung R. Administration of melatonin after onset of ischemia reduces the volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. Stroke. 2003;34:770–775
  69. Husson I, Mesples B, Bac P, Vamecq J, Evrard P, Gressens P. Melatoninergic neuroprotection of the murine periventricular white matter against neonatal excitotoxic challenge. Ann Neurol. 2002;51:82–92
  70. Lee MYKY, Chen HY, Chen TY, Chen ST, Huang CC, Yang IP, et al. Intravenous administration of melatonin reduces the intracerebral cellular inflammatory response following transient focal cerebral ischemia in rats. J Pineal Res. 2007;42:297–309
  71. Lee EJ, Wu TS, Lee MY, Chen TY, Tsai YY, Chuang JI, et al. Delayed treatment with melatonin enhances electrophysiological recovery following transient focal cerebral ischemia in rats. J Pineal Res. 2004;36:33–42
  72. Lee EJ, Lee MY, Chen HY, Hsu YS, Wu TS, Chen ST, et al. Melatonin attenuates gray and white matter damage in a mouse model of transient focal cerebral ischemia. J Pineal Res. 2005;38:42–52
  73. Lee MY, Kuan YH, Chen HY, Chen TY, Chen ST, Huang CC, et al. Intravenous administration of melatonin reduces the intracerebral cellular inflammatory response following transient focal cerebral ischemia in rats. J Pineal Res. 2007;42:297–309
  74. Chen HY, Chen TY, Lee MY, Chen ST, Hsu YS, Kuo YL, et al. Melatonin decreases neurovascular oxidative/nitrosative damage and protects against early increases in the blood–brain barrier permeability after transient focal cerebral ischemia in mice. J Pineal Res. 2006;41:175–182
  75. Welin AK, Svedin P, Lapatto R, Sultan B, Hagberg H, Gressens P, et al. Melatonin reduces inflammation and cell death in white matter in the mid-gestation fetal sheep following umbilical cord occlusion. Pediatr Res. 2007;61:153–158
  76. Hutton LC, Abbass M, Dickinson H, Ireland Z, DW W. Neuroprotective properties of melatonin in a model of birth asphyxia in the spiny mouse (acomys cahirinus). Dev Neurosci. 2009;31:437–451
  77. Miller SL, Yan EB, Castillo-Meléndez M, Jenkin G, DW W. Melatonin provides neuroprotection in the late-gestation fetal sheep brain in response to umbilical cord occlusion. Dev Neurosci. 2005;27:200–210
  78. Lin H, Lee E. Effects of melatonin in experimental stroke models in acute, sub-acute, and chronic stages. Neuropsychiatr Die Treat. 2009;5
  79. Olivier P, Fontaine RH, Loron G, Van Steenwinckel J, Biran V, Massonneau V, et al. Melatonin promotes oligodendroglial maturation of injured white matter in neonatal rats. PLoS ONE. 2009;22:e7128
  80. Bouslama M, Renaud J, Olivier P, Fontaine RH, Matrot B, Gressens P, et al. Melatonin prevents learning disorders in brain-lesioned newborn mice. Neuroscience. 2007;150:712–719
  81. Ohls RK, Ehrenkranz RA, Das A, Dusick AM, Yolton K, Romano E, et al. Neurodevelopmental outcome and growth at 18 to 22months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics. 2004;114:1287–1291
  82. Ruth V, Widness JA, Clemons G, Raivio KO. Postnatal changes in serum immunoreactive erythropoietin in relation to hypoxia before and after birth. J Pediatr. 1990;116:950–954
  83. Maiese K, Li F, ZZ C. New avenues of exploration for erythropoietin. JAMA. 2005;293:90–95
  84. Kellert BA, McPherson RJ, SE J. A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats. Pediatr Res. 2007;61:451–455
  85. Gonzalez FF, McQuillen P, Mu D, Chang Y, Wendland M, Vexler Z, et al. Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke. Dev Neurosci. 2007;29:321–330
  86. Gonzalez FF, Abel R, Almli CR, Mu D, Wendland M, DM F. Erythropoietin sustains cognitive function and brain volume after neonatal stroke. Dev Neurosci. 2009;31:403–411
  87. Palmer C, Menzies SL, Roberts RL, Pavlick G, JR C. Changes in iron histochemistry after hypoxic-ischemic brain injury in the neonatal rat. J Neurosci Res. 1999;56:60–71
  88. Juul SE, McPherson RJ, Farrell FX, Jolliffe L, Ness DJ, CA G. Erytropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol Neonate. 2004;85:138–144
  89. Zhu C, Kang W, Xu F, Cheng X, Zhang Z, Jia L, et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics. 2009;124:e218–226
  90. Cariou A, Claessens YE, Pène F, Marx JS, Spaulding C, Hababou C, et al. Early high-dose erythropoietin therapy and hypothermia after out-of-hospital cardiac arrest: a matched control study. Resuscitation. 2008;76:397–404
  91. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40:e647–656
  92. Laudenbach V, Mantz J, Lagercrantz H, Desmonts JM, Evrard P. Effects of alpha(2)-adrenoceptor agonists on perinatal excitotoxic brain injury: comparison of clonidine and dexmedetomidine. Anaesthesiology. 2002;96:134–141P G
  93. Dean JM, George S, Naylor AS, Mallard C, Gunn AJ, Bennet L. Partial neuroprotection with low-dose infusion of the alpha2-adrenergic receptor agonist clonidine after severe hypoxia in preterm fetal sheep. Neuropharmacology. 2008;55:166–174
  94. Ma D, Hossain M, Rajakumaraswamy N, Arshad M, Sanders RD, Franks NP, et al. Dexmedetomidine produces its neuroprotective effect via the alpha 2a-adrenoceptor subtype. Eur J Pharmacol. 2004;502:87–97
  95. Matsumoto M, Zornow MH, Rabin BC, Maze M. The alpha 2 adrenergic agonist, dexmedetomidine, selectively attenuates ischemia-induced increases in striatal norepinephrine concentrations. Brain Res. 1993;627:325–329
  96. Rajakumaraswamy N, Ma D, Hossain M, Sanders RD, Franks NP, Maze M. Neuroprotective interaction produced by xenon and dexmedetomidine on in vitro and in vivo neuronal injury models. Neurosci Lett. 2006;409:128–133
  97. Paris A, Mantz J, Tonner PH, Hein L, Brede M. The effects of dexmedetomidine on perinatal excitotoxic brain injury are mediated by the alpha2a-adrenoceptor subtype. Anaesth Analg. 2006;102:456–461P G
  98. Hoffman WE, Kochs E, Werner C, Thomas C. Dexmedetomidine improves neurologic outcome from incomplete ischemia in the rat. Reversal by the alpha 2-adrenergic antagonist atipamezole. Anaesthesiology. 1991;75:328–332RF A
  99. Maier C, Steinberg GK, Sun GH, Zhi GT. Neuroprotection by the alpha 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anaesthesiology. 1993;79:306–312MM
  100. Engelhard K, Werner C, Eberspächer E, Bachl M, Blobner M, Hildt E, et al. The effect of the alpha 2-agonist dexmedetomidine and the n-methyl-d-aspartate antagonist s(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anaesth Analg. 2003;96:524–531
  101. Sanders RD, Xu J, Shu Y, Januszewski A, Halder S, Fidalgo A, et al. Dexmedetomidine attenuates isoflurane-induced neurocognitive impairment in neonatal rats. Anaesthesiology. 2009;110:1077–1085
  102. Chrysostomou C, De Toledo JS, Avolio T, Motoa MV, Berry D, Morell VO, et al. Dexmedetomidine use in a pediatric cardiac intensive care unit: can we use it in infants after cardiac surgery?. Pediatr Crit Care Med. 2009;10:654–660
  103. Glass HC, Glidden D, Jeremy RJ, Barkovich AJ, Ferriero DM, Miller SP. Clinical neonatal seizures are independently associated with outcome in infants at risk for hypoxic-ischemic brain injury. J Pediatr. 2009;155:318–323
  104. Wirrell EC, Armstrong EA, Osman LD, Yager JY. Prolonged seizures exacerbate perinatal hypoxic-ischemic brain damage. Pediatr Res. 2001;50:445–454
  105. Miller SP, Weiss J, Barnwell A, Ferriero DM, Latal-Hajnal B, Ferrer-Rogers A, et al. Seizure-associated brain injury in term newborns with perinatal asphyxia. Neurology. 2002;58:542–548
  106. Calabresi P, Cupini LM, Centonze D, Pisani F, Bernardi G. Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia. Ann Neurol. 2003;53:693–702
  107. Kim JM, Kwon S, Seo HE, Choe BH, Cho MH, Park SP. Long-term effectiveness and tolerability of topiramate in children with epilepsy under the age of 2years: 4-year follow-up. J Korean Med Sci. 2009;24:1078–1082
  108. Taverna S, Sancini G, Mantegazza M, Franceschetti S, Avanzini G. Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther. 1999;288:960–968
  109. Zona C, Ciotti MT, Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett. 1997;231:123–126
  110. Herrero AI, Del Olmo N, González-Escalada JR, Solis JM. Two new actions of topiramate: inhibition of depolarizing gaba(a)-mediated responses and activation of a potassium conductance. Neuropharmacology. 2002;42:210–220
  111. White H.S., Brown S.D., Woodhead J.H., Skeen G.A., HH W: Topiramate enhances gaba-mediated chloride flux and gaba-evoked chloride currents in murine brain neurons and increases seizure threshold. 1997 2000;28:167-179.
  112. Noh MR, Kim SK, Sun W, Park SK, Choi HC, Lim JH, et al. In: Neuroprotective effect of topiramate on hypoxic ischemic brain injury in neonatal rats. vol. 201:2006;p. 2
  113. Follett PL, Deng W, Dai W, Talos DM, Massillon LJ, Rosenberg PA, et al. Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate. J Neurosci. 2004;24:4412–4420
  114. Schubert S, Brandl U, Brodhun M, Ulrich C, Spaltmann J, Fiedler N, et al. Neuroprotective effects of topiramate after hypoxia-ischemia in newborn piglets. Brain Res. 2005;1058:129–136
  115. Kim J, Kondratyev A, Gale K. Antiepileptic drug-induced neuronal cell death in the immature brain: effects of carbamazepine, topiramate, and levetiracetam as monotherapy versus polytherapy. J Pharmacol Exp Ther. 2007;323:165–173
  116. Filippi L, la Marca G, Fiorini P, Poggi C, Cavallaro G, Malvagia S, et al. Topiramate concentrations in neonates treated with prolonged whole body hypothermia for hypoxic ischemic encephalopathy. Epilepsia. 2009;50:2355–2361
  117. Fürwentsches A, Bussmann C, Ramantani G, Ebinger F, Philippi H, Pöschl J, et al. Levetiracetam in the treatment of neonatal seizures: a pilot study. Seizure. 2010;19:185–189
  118. Mazarati AM, Baldwin R, Klitgaard H, Matagne A. Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Res. 2004;58:167–174CG W
  119. Hanon E, Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure. 2001;10:287–293
  120. Kim JS, Kondratyev A, Tomita Y. Neurodevelopmental impact of antiepileptic drugs and seizures in the immature brain. Epilepsia. 2007;48:19–26K G
  121. Murry C, Jennings R, Reimer K. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124–1136
  122. Yellon D, Downey J. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003;83:1113–1151
  123. Pignataro G, Meller R, Inoue K, Ordonez A, Ashley M, Xiong Z, et al. In vivo and in vitro characterization of a novel neuroprotective strategy for stroke: ischemic postconditioning. J Cereb Blood Flow Metab. 2008;28(2):232–241
  124. Zhao Z, Corvera J, Halkos M, Kerendi F, Wang N, Guyton R, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003;285:H579–588
  125. Thibault H, Piot C, Ovize M. Postconditioning in man. Heart Fail Rev. 2007;12:245–248
  126. Zhao H, Sapolsky R, Steinberg G. Interrupting reperfusion as a stroke therapy: ischemic postconditioning reduces infarct size after focal ischemia in rats. J Cereb Blood Flow Metab. 2006;26:1114–1121
  127. Wang J, Shen J, Gao Q, Ye Z, Yang S, Liang H, et al. Ischemic postconditioning protects against global cerebral ischemia/reperfusion-induced injury in rats. Stroke. 2008;39:983–990
  128. Ren C, Gao X, Niu G, Yan Z, Chen X, Zhao H. Delayed postconditioning protects against focal ischemic brain injury in rats. PLoS ONE. 2008;3:e3851
  129. Ren C, Gao X, Steinberg G, Zhao H. Limb remote-preconditioning protects against focal ischemia in rats and contradicts the dogma of therapeutic time windows for preconditioning. Neuroscience. 2008;151:1099–1103
  130. Zhao H. Ischemic postconditioning as a novel avenue to protect against brain injury after stroke. J Cereb Blood Flow Metab. 2009;29:873–885
  131. Bartley J, Soltau T, Wimborne H, Kim S, Martin-Studdard A, Hess D, et al. Brdu-positive cells in the neonatal mouse hippocampus following hypoxic-ischemic brain injury. BMC Neurosci. 2005;6:15
  132. Yang Z, Covey MV, Bitel CL, Ni L, Jonakait GM, Levison SW. Sustained neocortical neurogenesis after neonatal hypoxic/ischemic injury. Ann Neurol. 2007;61:199–208
  133. Ong J, Plane JM, Parent JM, Silverstein FS. Hypoxic-ischemic injury stimulates subventricular zone proliferation and neurogenesis in the neonatal rat. Pediatr Res. 2005;58:600–606
  134. van Velthoven CT, Kavelaars A, van Bel F. Regeneration of the ischemic brain by engineered stem cells: fuelling endogenous repair processes. Brain Res Rev. 2009;61:1–13CJ H
  135. Qu R, Li Y, Gao Q, Shen L, Zhang J, Liu Z, et al. Neurotrophic and growth factor gene expression profiling of mouse bone marrow stromal cells induced by ischemic brain extracts. Neuropathology. 2007;27

PII: S0378-3782(10)00109-X

doi: 10.1016/j.earlhumdev.2010.05.011

Early Human Development
Volume 86, Issue 6 , Pages 369-377 , June 2010

Article Tools

* Image Usage & Resolution